Journal
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Volume 40, Issue 6, Pages 446-460Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08923973.2018.1469144
Keywords
Inflammatory bowel disease; Crohn's disease; ulcerative colitis; antibodies; monoclonal; fecal microbiota transplantation
Categories
Ask authors/readers for more resources
Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. This review describes the hallmark immunobiology of Crohn's disease and ulcerative colitis as well as therapeutic targets and mechanisms of action for current, experimental, and future treatments in IBD. Conventional therapies include 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and methotrexate. Since 1997, monoclonal antibodies have gained widespread use. These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin (IL)-12, and IL-23, or anti-homing antibodies directed against alpha 4 beta 7 integrin. Emerging oral therapies include modulators of intracellular signal transduction such as Janus kinase inhibitors. Vitamin D may help to regulate innate and adaptive immune responses. Modulation of the intestinal microbiota, using live microorganisms (probiotics), substrates for the colonic microbiota (prebiotics), or fecal microbiota transplantation (FMT), is in development. Dietary supplements are in widespread use, but providing evidence for their benefit is challenging. Stem cell treatment and nervous stimulation are promising future treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available